ArticleTherapeutic innovation & regulatory science2026
Pharmacovigilance Data From Digital Health Systems: Regulations, Implications, and Opportunities-A TransCelerate Perspective.
Article in Therapeutic innovation & regulatory science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Digital health technologies (DHTs) represent a clear potential to advance the science of pharmacovigilance and promote patient safety. A project was created to assess the current landscape for use of DHTs and identify opportunities to use DHTs in fulfilling these objectives. TransCelerate Biopharma Inc, a non-profit launched in 2012 to accelerate and enhance research of human medicines, led an assessment of digital health in pharmacovigilance focused on the global regulatory landscape. This was achieved through first identifying and forming a glossary of applicable terminology and compiling an index of related regulations, guidelines, and source materials from global health authorities. Using this information, a regulatory landscape assessment was performed, and an industry survey designed. Both outputs indicated that the use of DHTs in pharmacovigilance applications in the pharmaceutical industry is in early development stages for both regulations and real-world utilization. This insight led TransCelerate to develop a tool that would enable a robust exploration of individual DHTs used in the post approval setting through the lens of pharmacovigilance professionals, through proposed considerations for enhancing product safety. This work is intended to positively support the industry in understanding the use and impact of DHTs on pharmacovigilance and readiness. There remains an opportunity to set forth guiding principles and a framework, in collaboration with regulators, healthcare professionals, systems, and patients for DHTs to advance the science of pharmacovigilance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.